Chemical Epigenetics

Antonello Mai is Full Professor of Medicinal Chemistry in the Faculty of Pharmacy and Medicine in Sapienza University of Rome from 2011. He took his Degree in Pharmacy in 1984 (full marks) and then his PhD in Medicinal Chemistry and Pharmaceutical Sciences in 1992 in Sapienza. In 1998 he was appointed as Associate Professor of Medicinal Chemistry in the Faculty of Pharmacy in Sapienza. From 2012 to 2018 he was the Coordinator of the PhD Course in Pharmaceutical Science, and from 2013 to 2019 he was President of the Degree Course in Pharmaceutical Chemistry and Technologies in Sapienza. From 2004 to 2009, A. Mai was a member of the Executive Committee of the Medicinal Chemistry Division of the Italian Chemical Society and from 2009 to 2014 he was a member of the Scientific Committee of the European School of Medicinal Chemistry. He is Editor of "ChemMedChem" (Wiley),Regional Editor of 'Mini Reviews in Medicinal Chemistry" and "Medicinal Chemistry" (Bentham), Associate Editor of Clinical Epigenetics (Springer) and of Journal of Enzyme Inhibition and Medicinal Chemistry (Taylor and Francis). His working experience has been devoted to synthesis of new potential bio-active compounds, particularly in the field of epigenetics (from 1999, inhibitors of HDACs, HATs, sirtuins, PRMTs, HKMTs, KDMs and DNMTs). A. Mai is author of more than 280 publications on highly impacted international Journals [h-index = 52] and 3 book chapters.

Targeting the Zinc-Dependent Histone Deacetylases (HDACs) for Drug Discovery.- Hydroxamic Acid-Containing Peptides in the Study of Histone Deacetylases.- Sirtuin Inhibitors and Activators.- Histone Acetyltransferase Enzymes: From Biological Implications to Most Relevant Inhibitors.- Lysine Methyltransferases and Their Inhibitors.- PRMT Inhibitors.- Lysine-Specific Histone Demethylases 1/2  (LSD1/2) and Their Inhibitors.- Inhibitors of JmjC-Containing Histone  Demethylases.- Chemical Compounds Targeting DNA Methylation and Hydroxymethylation.- Applied Biophysics for Bromodomain Drug Discovery.- Methyl-Readers and Inhibitors.- Altered Long Non-coding RNA Expression in Cancer: Potential Biomarkers and Therapeutic Targets? - Acetylation and Methylation in Asthma, COPD, and Lung Cancer.- Structure-Based Design ofEpigenetic Inhibitors.- Experimental Methodologies for Detection and Mapping of Epigenetic DNA Marks.- Advanced Assays in Epigenetics.